Preclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus

Preclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus

There are currently no prophylactic vaccines licensed to protect against Lassa fever caused by Lassa virus (LASV) infection. The Emergent BioSolutions (EBS) vaccine candidate, EBS-LASV, is being developed for the prevention of Lassa fever. EBS-LASV is a live-attenuated recombinant Vesicular Stomatit...

Full description

Bibliographic Details
Main Authors: Demetrius Matassov, Lisa Evans DeWald, Stefan Hamm, Rebecca M. Nowak, Cheryl S. Gerardi, Theresa E. Latham, Rong Xu, Amara Luckay, Tracy Chen, Marc Tremblay, Jeffry Shearer, Melissa Wynn, John H. Eldridge, Kelly Warfield, Kevin Spurgers
Format: Article
Language:English
Published: MDPI AG 2024-07-01
Series:Vaccines
Subjects:
Lassa virus
LASV
glycoprotein
vesicular stomatitis virus
VSV
attenuated vaccine
Online Access:https://www.mdpi.com/2076-393X/12/8/858

Internet

https://www.mdpi.com/2076-393X/12/8/858

Similar Items